Jazz Pharmaceuticals Plc said on Wednesday it had agreed to buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal which will bolster its neuroscience business with the addition of a cannabis-based epilepsy treatment.
GW Pharma's Epidiolex, the first marijuana-derived drug to be approved in the United States, generated sales of over $500 million for the U.K.-based company last year. Analysts expect sales to breach $1 billion soon.
The drug was approved in June 2018 for use in patients aged two years and older with rare childhood-onset forms of epilepsy that are among the most resistant to treatment. It has since received wider approvals, including in children of one year and older.
The deal took some cannabis-focused exchange-traded funds (ETFs) by surprise. Many saw it as a seal of approval for the medical marijuana industry by traditional pharma companies.
"Today could be a notable turning point as a more traditional pharma company has agreed to purchase GW Pharma," said Nawan Butt, portfolio manager of the Medical Cannabis and Wellness UCITS ETF.
Dan Ahrens, chief operating officer and portfolio manager at AdvisorShares, which manages the Pure Cannabis ETF, said: "We're surprised at the news... but not at all surprised by opportunity or the price."
"More and more companies are learning the benefits of cannabinoid products, and cannabis and cannabinoids products are rapidly gaining acceptance in the public eye and at a federal government level."
The deal will allow Jazz to move beyond sleep disorders and cancer treatments by beefing up its neuroscience unit.
Jazz Chairman and Chief Executive Bruce Cozadd said in an interview that in GW, Jazz is getting "a near-term blockbuster product in Epidiolex and a really exciting scientific platform around cannabinoid medicines, with early-to-late-stage clinical programs already in place."
Jazz will acquire GW for $220 per American depositary share - $200 in cash and $20 in Jazz shares. The offer represents a 50% premium to GW's Tuesday closing price.
GW shares were hovering around $214, while Jazz shares fell 2%.
Evercore and Guggenheim advised Jazz, according to the press release. Goldman Sachs & Co LLC and Centerview Partners LLC advised GW.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU